⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10380731 | 0.87 | — | — | |
| SCHEMBL9727638 | 0.82 | — | — | |
| SCHEMBL15959540 | 0.81 | ADRA2A (0.31) | — | |
| SCHEMBL9727364 | 0.81 | — | — | |
| SCHEMBL8040746 | 0.78 | — | — | |
| SCHEMBL10155857 | 0.77 | — | — | |
| SCHEMBL23576318 | 0.77 | — | — | |
| SCHEMBL11957462 | 0.77 | — | — | |
| SCHEMBL14917574 | 0.73 | ADRA2A (0.33) | — | |
| SCHEMBL25266 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-12-05 | — | — | US | claimed |
| US-12037456-B2 | Poly(2-oxazoline)s and methods for preparing them | UNIVERSITEIT GENT (BE) | 2024-07-16 | — | — | US | claimed |
| EP-4395748-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-07-10 | — | — | EP | claimed |
| CN-117940118-A | Novel lipid nanoparticles for nucleic acid delivery | 库瑞瓦格欧洲公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2023031394-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2023-03-09 | — | — | WO | claimed |
| EP-4731655-A1 | NUCLEIC ACID ENCODED ANTIBODIES | CureVac SE (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260076918-A1 | HETEROTELECHELIC COMPOUNDS | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-03-19 | — | — | US | disclosed |
| EP-4676446-A1 | NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025103803-A1 | IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | CureVac SE (DE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250099614-A1 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | CureVac SE (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250027108-A1 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | CureVac SE (DE) | 2025-01-23 | — | — | US | disclosed |
| WO-2024260570-A1 | NUCLEIC ACID ENCODED ANTIBODIES | CureVac SE (DE) | 2024-12-26 | — | — | WO | disclosed |
| US-5534640-A | REDUCING INFLAMMATION AND CELL PROLIFERATION, COGNITION ACTIVATORS, BACTERIOSTATS, FUNGISTATS | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5519062-A | ANTIINFLAMMATORY | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-05-21 | — | — | US | disclosed |
| US-5488063-A | ANTIINFLAMMATORY, ANTICARACINOGENIC AGENTS; BACTERICIDES, FUNGICIDES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5488061-A | ANTIINFLAMMATORY, ANTICARACINOGENIC AGENTS; BACTERICIDES, FUNGICIDES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5360811-A | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0470104-A1 | A PROCESS FOR MAKING 2-OXAZOLINES | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990013546-A1 | A PROCESS FOR MAKING 2-OXAZOLINES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-11-15 | — | — | WO | disclosed |
| EP-0394849-A1 | Process for the preparation of 2-oxazolines | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-10-31 | — | — | EP | disclosed |